Hematologic malignancies research is growing at a rapid pace, increasing the complexity of the field. Advances in the understanding of the mechanisms of hematologic malignancies have resulted in the development of new prognostic models, novel therapies, and improvements in disease management. It is essential to our community to stay abreast of the latest findings in the field and of their potential impaact on clinical practices.
This symposium will provide attendees with cutting-edge updates and perspectives on new diagnostic tools and management options of hematologic malignancies including genetic profiling, cytogenetics, molecular diagnostics, riskadaptive strategies, and novel therapies recently approved by the FDA. Advances in the understanding of aggressive/ indolent lymphoma, myelodysplasia, plasma cell dyscrasia, acute/chronic leukemia and myeloproliferative disease, will be addressed. Advances in newer therapeutic approaches in classical hematology will be reviewed in the Consultative Hematology section.
COMPLIMENTARY REGISTRATION
Registration Deadline: Monday, April 10, 2023
Details
VIRTUAL CME:Tuesday, April 11, 2023
5:00–9:30 pm EDT Exhibit Hall Open
6:00–8:50 pm EDT Education Program
8:50–9:20 pm EDT Virtual Q&A Reception & Exhibit Hall
Intended Audience
The program is designed for oncologists, hematologists, radiation oncologists, pathologists, internists, primary care physicians, fellows, physician assistants, nurse practitioners, oncology nurses, and social workers.
Inquiries
Lucía Tono, PhD, Med: 215-728-3797
Lucia.Tono-Ramirez@tuhs.temple.edu
Presenters
Program Director
Rashmi Khanal, MD
Assistant Professor, Department of Bone Marrow Transplant and Cellular Therapies
Faculty
Henry Fung, MD, FACP, FRCPE
Chair and Professor, Department of Bone Marrow Transplant and Cellular Therapies
Peter Abdelmessieh, DO, MSc
Assistant Professor, Department of Bone Marrow Transplant and Cellular Therapies
Iberia Romina Sosa, MD, PhD
Associate Professor, Department of Hematology/Oncology
Shazia Nakhoda, MD
Assistant Professor, Department of Hematology/Oncology
Asya Varshavsky-Yanovsky, MD, PhD
Assistant Professor, Department of Bone Marrow Transplant and Cellular Therapies
Marcus Messmer, MD
Assistant Professor, Department of Hematology/Oncology
Michael Styler, MD
Associate Professor, Department of Bone Marrow Transplant and Cellular Therapies
Learning Objectives
After participating in this educational program, learners should be able to:
- Summarize the findings from key clinical trials presented at the 2022 ASH meeting that will impact standards of care in hematology
- Discuss the latest findings in genetic profiling, cytogenetics, and molecular biology, and describe how this information can be utilized in determining patient prognosis and treatment course
- List novel, targeted therapies in development for hematology and explain the therapeutic rationale for these agents
- Describe the latest advances in the field of Consultative Hematology that will impact patient treatment
- Outline how clinical trial data can be efficiently incorporated into community-based hematology practice
Accreditation Statement
The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.
Designation Statement
The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity.